Abstract
Anti-tumor necrosis factor (TNF) antibodies are powerful therapeutic agents for the treatment of Crohn's disease. TNF has diverse proinflammatory effects within the intestinal mucosa and is a pivotal cytokine in the inflammatory cascade. Although anti-TNF antibodies exert a variety of anti-inflammatory effects by neutralizing the cytokine, these agents vary in their efficacy. Recent data suggest that the ability to bind transmembrane TNF is a key property necessary for efficacy. Transmembrane binding of TNF effects apoptosis of T cells, thereby alleviating a fundamental defect in Crohn's disease in the regulation of T cell populations.
MeSH terms
-
Animals
-
Antibodies / therapeutic use
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Apoptosis / physiology
-
Biological Therapy
-
Certolizumab Pegol
-
Crohn Disease / drug therapy
-
Crohn Disease / immunology
-
Crohn Disease / physiopathology*
-
Etanercept
-
Humans
-
Immunoglobulin Fab Fragments
-
Immunoglobulin G / therapeutic use
-
Infliximab
-
Polyethylene Glycols / therapeutic use
-
Receptors, Tumor Necrosis Factor / therapeutic use
-
Recombinant Fusion Proteins / therapeutic use
-
T-Lymphocytes / immunology
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
-
Tumor Necrosis Factor-alpha / immunology*
-
Tumor Necrosis Factor-alpha / physiology
Substances
-
Antibodies
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Immunoglobulin Fab Fragments
-
Immunoglobulin G
-
Receptors, Tumor Necrosis Factor
-
Recombinant Fusion Proteins
-
Tumor Necrosis Factor-alpha
-
CDP 571
-
Polyethylene Glycols
-
Infliximab
-
Etanercept
-
Certolizumab Pegol